Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

Saad, Fred; Winquist, Eric; Hubay, Stacey; Berry, Scott; Assi, Hazem; Lévesque, Éric; Aucoin, Nathalie; Czaykowski, Piotr; Lattouf, Jean‐Baptiste; Alloul, Karine; Stewart, John A.; Sridhar, Srikala S.

doi:10.1200/jco.2014.32.15_suppl.5062

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cabazitaxel outcomes have been investigated in a total of 10 retrospective analyses in docetaxel and ARAT therapypretreated patients (docetaxel-abiraterone-cabazitaxel or docetaxel-enzalutamide-cabazitaxel [D-A/E-C] sequences; Table 2) [32,69,[79][80][81][82][83][84][85]. Findings from these cohort analyses also show substantial variability, with ≥50% PSA decline data ranging from 25% to 46% (n = 8 cohorts; Table 2).…”

Section: Prognostic and Predictive Clinical Factors And Modelsmentioning

confidence: 99%

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

et al. 2015

View full text Add to dashboard Cite

This systematic review assembles current evidence and provides an approach to treatment using available clinical factors. Issues of patient selection, use of laboratory and clinical biomarkers to identify patients at risk of poor outcomes, and the timing and sequencing of available treatment options are addressed. Our findings reveal a lack of high-level evidence regarding predictive factors and treatment of patients with resistance to ARAT therapy, and a need for further research in this area. In the meantime, we suggest practical strategies to guide management of ARAT treatment-resistant patients based on available data.

show abstract

Section: Prognostic and Predictive Clinical Factors And Modelsmentioning

confidence: 99%

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The global EAP analysis indicates regional variation, with 10.8–29.8% patients having received more than 10 cycles of treatment . Within Europe, up to 16 cycles were administered in some patients, and in Canada up to 27 treatment cycles have been administered with no deterioration in the patients' quality of life . An analysis of the UK dataset indicates that the proportion of patients reporting no pain increased with more cycles of cabazitaxel, such that it had improved from 22.3% at baseline to 57.1% at cycle 10 …”

Section: Dosage and Administrationmentioning

confidence: 99%

Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia

Parente

Bahre

2015

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option for patients who have progressed despite docetaxel therapy. Clinical use of cabazitaxel in mCRPC is based on the results of the TROPIC study, which demonstrated an approximately 30% reduction in the risk of death compared with mitoxantrone. In this paper, we draw on accumulating clinical experience with cabazitaxel in Australia to discuss important questions such as how to select the right patient for treatment and how to proactively prevent and manage toxicities associated with this therapy. Recognizing the need for a multidisciplinary approach to patient care, opinion and insight has been sought from medical oncologists, nurses and pharmacists. While lack of trial data means that a number of questions remain unanswered, local clinical experience has helped to guide treatment decisions and refine management protocols. Appropriate patient selection, careful ongoing monitoring and proactive management of adverse events will ensure optimal treatment of patients. Nurses in particular play an important role in educating patients and identifying patients at increased risk of developing adverse events with cabazitaxel. The oncology team must work together to educate patients; taking a proactive approach to issues such as adverse events will help maximize the clinical outcome of cabazitaxel treatment and impact positively on the patient's quality of life.

show abstract

“…33 Prior Treatment Effect on Cabazitaxel Efficacy Based on the findings of 5 retrospective studies, the efficacy of cabazitaxel may be unaffected by prior abiraterone or enzalutamide treatment. [34][35][36]40,41 In particular, 2 studies that compared the efficacy of cabazitaxel in docetaxeltreated patients who either had or had not received prior abiraterone or enzalutamide found no difference in efficacy. 36,40 These findings are consistent with preclinical experiments showing cross-resistance between enzalutamide and docetaxel, but not cabazitaxel.…”

Section: Continuedmentioning

confidence: 99%

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer

Shore

Heidenreich

Saad

2017

Urology

Self Cite

View full text Add to dashboard Cite

Optimal sequencing strategies for approved agents in metastatic castration-resistant prostate cancer (mCRPC) are unclear. Retrospective clinical studies suggest cross-resistance between specific therapies. This review assesses treatment decisions for mCRPC. Increased use of chemohormonal therapy in castration-sensitive disease may affect subsequent treatment decisions in mCRPC. Initial abiraterone or enzalutamide treatment may result in cross-resistance for subsequent androgen receptor-targeted therapy. Clinical responses may be seen in both docetaxel- and cabazitaxel-treated patients progressing after treatment with abiraterone or enzalutamide. These observations are supported by proposed resistance mechanisms. In conclusion, small, retrospective studies suggest cross-resistance between specific therapies in mCRPC. Larger prospective studies are required.

show abstract

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

Cited by 5 publications

References 0 publications

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state

Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About